Coherus BioSciences, Inc. (CHRS) Financials
CHRS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 629.6 million | 823.0 million |
2023-09-30 | 583.8 million | 717.4 million |
2023-06-30 | 469.6 million | 644.4 million |
2023-03-31 | 402.4 million | 598.9 million |
CHRS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -13.0 million | 10.8 million |
2023-09-30 | -54.3 million | 10.0 million |
2023-06-30 | -39.0 million | 10.1 million |
2023-03-31 | -68.9 million | 12.3 million |
CHRS Net Income
No data available :(
CHRS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 117.7 million | - | 7.5 million |
2023-09-30 | 131.1 million | - | 5.9 million |
2023-06-30 | 144.7 million | 226.2 million | 7.1 million |
2023-03-31 | 128.1 million | 225.9 million | 8.2 million |
CHRS Shares Outstanding
CHRS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 34000 | 25.3 million | 49.5 million | - |
2023-09-30 | - | 25.6 million | 48.2 million | - |
2023-06-30 | 100000 | 23.3 million | 45.1 million | - |
2023-03-31 | 152000 | 34.2 million | 49.2 million | - |
CHRS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 91.5 million | 85.6 million |
2023-09-30 | 74.6 million | 32.7 million |
2023-06-30 | 58.7 million | 24.8 million |
2023-03-31 | 32.4 million | 16.9 million |
CHRS
Price: $2.04
52 week price:
Earnings Per Share: -2.53 USD
P/E Ratio: -1.03
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 749400
Ebitda: -55.8 millionMarket Capitalization: 251.4 million